Your search for

62 results were returned

  1. Legal news
    16 May 2019
    Report from Med-Tech Innovation Expo 2019
    www.twobirds.com/en/news/articles/2019/uk/bird-and-birds-ewan-grist-chris-de-mauny-and-toby-bond-spoke-at-the-med-tech-innovation-expo

    Ewan explored the legal issues which arise at various stages of the lifecycle of a medical device; from product concept, though prototyping, testing, refinement, manufacture, marketing and placing on the market.

  2. Legal news
    25 February 2021
    International Comparative Legal Guide to Digital Health 2021
    www.twobirds.com/en/news/articles/2021/uk/international-comparative-legal-guide-to-digital-health2021

    The 2nd edition of the International Comparative Legal Guide to Digital Health 2021 is a practical cross-border insight into digital health law. Sally Shorthose, Toby Bond, Philippe Bradley-Schmieg and Pieter Erasmus ...

  3. Legal news
    29 April 2021
    London & the life sciences
    www.twobirds.com/en/news/articles/2021/uk/london-and-the-life-sciences

    Europe’s biotech industry is more buoyant now than it’s ever been. A combination of eager investors, the high-speed development of COVID-19 vaccines, exciting scientific developments and last year’s acceleration of ...

  4. Legal news
    02 July 2018
    Arrow still flies
    www.twobirds.com/en/news/articles/2018/uk/arrow-still-flies

    During 2016 and 2017 the complex litigation about part of AbbVie's patent portfolio protecting its Humira/adalimumab product drew attention in part because of the granting of a so-called Arrow declaration.

  5. Legal news
    14 September 2018
    Patents: interpretation of Supplementary Protection Certificate Regulation
    www.twobirds.com/en/news/articles/2018/uk/patents-interpretation-of-supplementary-protection-certificate-regulation

    The European Court of Justice (ECJ) has ruled that a product composed of several active ingredients with a combined effect may be protected by a basic patent in force under the Supplementary Protection Certificate (SPC) ...

  6. Legal news
    22 December 2020
    High Court considers requirements for an exclusive patent licence (Neurim v Mylan)
    www.twobirds.com/en/news/articles/2020/uk/high-court-considers-requirements-for-an-exclusive-patent-licence

    In the LexisNexis case analysis, Senior IP Associate, Will Smith, talks about the decision in the following matter: Neurim Pharmaceuticals (1991) Ltd & Anor v Generics UK Ltd (t\a MYLAN) [2020] EWHC 3270 (Pat). This ...

  7. Legal news
    21 January 2020
    Transfers of value to “influencers”: new disclosure obligation for companies in the health sector
    www.twobirds.com/en/news/articles/2020/uk/transfers-of-value-to-influencers-new-disclosure-obligation-for-companies-in-the-health-sector

    The list of beneficiaries of transfers of value subject to compulsory disclosure in the French public “transparency” database include “persons who, in the media or on social media, present one or several health ...

  8. Legal news
    24 June 2020
    UK Supreme Court upholds Kymab's appeal imposing a stricter interpretation of sufficiency of disclosure for patents
    www.twobirds.com/en/news/articles/2020/uk/uk-supreme-court-upholds-kymabs-appeal

    In a judgment handed down today the UK Supreme Court has upheld the appeal of Kymab who had challenged Regeneron's patents covering Kymab's 'Kymouse' transgenic mouse.

  9. Legal news
    08 May 2019
    Patents: obviousness in relation to patent for dosage regime
    www.twobirds.com/en/news/articles/2019/global/patents-obviousness-in-relation-to-patent-for-dosage-regime

    The Supreme Court has confirmed that a patent for a dosage regime of a drug used to treat erectile dysfunction (ED) was obvious over the prior art.

  10. Legal news
    04 September 2019
    Patents: meaning of enablement in anticipation by prior art
    www.twobirds.com/en/news/articles/2019/global/patents-meaning-of-enablement-in-anticipation-by-prior-art

    The Patents Court has considered enablement in relation to anticipation of a claimed monoclonal antibody invention by prior art, and held the patent was invalid for lack of novelty; it was also obvious for lack of ...